Kineta Company Overview
Kineta
About Kineta
Kineta (NASDAQ:KA) focuses on developing novel immunotherapies aimed at transforming the lives of patients battling cancer and infectious diseases. With a robust pipeline that leverages cutting-edge science, their projects range from early preclinical studies to advanced clinical trials. Kineta's key objective is to harness the power of the immune system to fight disease, striving to bring innovative treatments from bench to bedside efficiently and effectively. The company's pursuit of breakthrough therapies highlights its commitment to addressing unmet medical needs and improving patient outcomes.
What is Kineta known for?
Snapshot
2006
Year founded
11
Employees
Mercer Island, United States
Head office
Loading Map...
Operations
All Locations
United States
Products and/or services of Kineta
- Development of novel immune-modulating therapies for cancer and chronic diseases focused on enhancing the body's natural defense mechanisms.
- Research and advancement in antiviral compounds targeting life-threatening viruses such as Ebola and influenza.
- Creation of innovative pain management solutions, leveraging non-opioid based treatments to address chronic pain without addiction risks.
- Design of a portfolio of biologics aimed at autoimmune diseases, aiming to restore immune system balance.
- Advancement in vaccine adjuvant technology to enhance the efficacy and durability of vaccines.
- Collaboration on the development of targeted therapies that modulate specific pathways involved in cancer and immune system disorders.
Kineta executive team
- Mr. Craig W. PhilipsPresident & Secretary
- Mr. Keith A. BakerChief Financial Officer
- Dr. Thierry Guillaudeux Ph.D.Chief Scientific Officer
- Mr. Gary GentgesExecutive Vice President of Corporate Development
- Ms. Pauline Kenny Esq., J.D.Advisor